Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Veliparib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 21 Sep 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History